



IFW

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 18, 2004 Signature: Shawn P. Foley
(Shawn P. Foley)

Docket No.:
CELLTH 3.0-003 CONT CONT XVI
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Warrell et al.

Application No.: 10/759,290

Group Art Unit: 1616

Filed: January 16, 2004

Examiner: A. N. Pryor

For: PROCESS FOR PRODUCING ARSENIC
TRIOXIDE FORMULATIONS AND
METHODS FOR TREATING CANCER USING
ARSENIC TRIOXIDE OR MELARSOPROL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

REQUEST FOR CONSIDERATION OF INFORMATION UNDER 37 CFR § 1.97 (C)

Dear Sir:

It is respectfully requested that the references cited in the enclosed form be considered pursuant to 37 C.F.R. § 1.97(c). Please charge Deposit Account No. 12-1095 in the amount of \$180.00 pursuant to 37 C.F.R. § 1.17(p). In the event that any additional fee is due in connection with the present request, the same should be charged to our Deposit Account No. 12-1095.

Dated: August 18, 2004

Respectfully submitted,

By Shawn P. Foley
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant



Notice: This correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: August 18, 2004

Signature:

Shawn P. Foley
(Shawn P. Foley)

Docket No.:
CELLTH 3.0-003 CONT CONT XVI
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Warrell et al.

Application No.: 10/759,290

Group Art Unit: 1616

Filed: January 16, 2004

Examiner: A. N. Pryor

For: PROCESS FOR PRODUCING ARSENIC
TRIOXIDE FORMULATIONS AND
METHODS FOR TREATING CANCER USING
ARSENIC TRIOXIDE OR MELARSOPROL

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Dear Sir:

It is respectfully requested that the references listed on the enclosed form be made of record and considered with respect to the above-referenced U.S. patent application. A copy of each reference was of record in United States Patent 6,723,351, the benefit of which is claimed under §120. Submission of the present Information Disclosure Statement should not be taken as an admission that the cited references are legally available prior art or that the same are pertinent or material.

In the event that any fee is due in connection with the present Information Disclosure Statement, the Commissioner is hereby authorized to charge the same to our Deposit Account

08/25/2004 GWORDOF1 00000017 121095 10759290

01 FC:1806 180.00 DA

Application No.: 10/759,290

Docket No.: CELLTH 3.0-003 CONT CONT XVI

No. 12-1095.

Dated: August 18, 2004

Respectfully submitted,

By Shawn P. Foley
Shawn P. Foley
Registration No.: 33,071
LERNER, DAVID, LITTENBERG,
KRUMHOLZ & MENTLIK, LLP
600 South Avenue West
Westfield, New Jersey 07090
(908) 654-5000
Attorney for Applicant

510407_1.DOC



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/759,290 |
| | | | | Filing Date | January 16, 2004 |
| | | | | First Named Inventor | Raymond P. Warrell, Jr. |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | A. N. Pryor |
| Sheet | 1 | of | 5 | Attorney Docket Number | CELLTH 3.0-003 CONT CONT XVI |

| U.S. PATENT DOCUMENTS | | | | | |
|-----------------------|--------------------------|--|--------------------------------|--|---|
| Examiner Initials* | Cite No. ¹ | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
| | | Number-Kind Code ² (if known) | | | |
| | AA** | US-132,275-B1 | 10-15-1872 | Gettings | |
| | AB** | US-232,807 | 10-05-1886 | Dennett | |
| | AC** | US-3,700,498 | 10-24-1972 | Kanazawa et al. | |
| | AD** | US-4,497,780 | 02-05-1985 | Barin et al. | |
| | AE** | US-5,759,837 | 06-02-1998 | Kuhajda et al. | |
| | AF** | US-2002/0183385 | 12-05-2002 | Ellison et al. | |
| | AG** | US-6,720,011 | 04-13-2004 | Zhang, Ting-Dong | |
| | AH** | US-6,770,304 | 08-03-2004 | Warrell et al. | |
| | AI** | US-2003/0099719 | 05/2003 | Warrell et al. | |
| | AJ** | US-6,723,351 | 04-20-2004 | Warrell et al. | |
| | AK** | US-6,773,792 | 05-11-2004 | Lu | |

| FOREIGN PATENT DOCUMENTS | | | | | | |
|--------------------------|--------------------------|---|-----------------------------------|--|---|----------------|
| Examiner Initials* | Cite No. ¹ | Foreign Patent Document | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T ⁶ |
| | | Country Code ³ -Number ⁴ -Kind Code ⁵ (if known) | | | | |
| | BA | JP-51-88620 | 03-08-1976 | | | |
| | BB | WO-95/01789 | 01-19-1995 | | | |
| | BC | CN-1133725 | 10-23-1996 | | | |
| | BD | CN-1131037 | 09-18-1996 | | | |
| | BE | CN-1122700 | 05-22-1996 | | | |
| | BF | CN-1081104 | 01-26-1994 | | | |
| | BG | CN-1119113 | 03-27-1996 | | | |
| | BH | CN-1061908 | 06-17-1992 | | | |
| | BI | CN-1121807 | 05-08-1996 | | | |
| | BJ | CN-1079391 | 12-15-1993 | | | |
| | BK | WO-94/02103 | 02-03-1994 | | | |
| | BL | FR-2 539 993 | 03-31-1994 | | | |
| | BM | DE-43 17 331 | 12-01-1994 | | | |
| | BN | WO-95/22336 | 08-24-1995 | | | |
| | BO | LV-11667 | 06-20-1997 | | | |
| | BP | WO-94/02108 | 02-03-1994 | | | |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. **CITE NO.: Those patent(s) or publication(s) which are marked with an double asterisk (**) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

| NON PATENT LITERATURE DOCUMENTS | | | |
|---------------------------------|--------------------------|---|----------------|
| Examiner Initials* | Cite No. ¹ | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T ² |
| | CA | CUTLER et al., Article IV, American Journal of the Medical Sciences, pp. 74-84, January 1878 | |
| | CB | FORKNER et al., "Arsenic as a therapeutic agent in chronic myelogeneous leukemia", Jour. | |

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/759,290 |
| | | | | Filing Date | January 16, 2004 |
| | | | | First Named Inventor | Raymond P. Warrell, Jr. |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | A. N. Pryor |
| Sheet | 2 | of | 5 | Attorney Docket Number | CELLTH 3.0-003 CONT CONT XVI |

| | | | |
|--|-----|--|--|
| | | A.M.A. 97(1):3-5, 1931 | |
| | CC | STEPHENS, et al., "The therapeutic effect of solution of potassium arsenite in chronic myelogenous leukemia", University of Rochester, pp. 1488-1502, 1936 | |
| | CD | NEUBAUER, "Arsenical cancer: a review", Arsenic Committee of the Medical Research Council, pp. 192-251, 1947 | |
| | CE | SHIBUYA, "Studies on experimental arsenious acid poisoning", Tokyo Jikeikai Ika Daigaku Zasshi, 86(4):653-675, 1971 | |
| | CF | PORIES et al., "Trace elements that act to inhibit neoplastic growth", Annals of New York Academy of Sciences, 199:265-273, June 25, 1972 | |
| | CG | MONFARDINI et al., "Survival in chronic myelogenous leukemia: influence of treatment and extent of disease at diagnosis", Cancer 31: 492-501, 1973 | |
| | CH | KERKVLiet et al., "Immunotoxicology Studies of Sodium Arsenate-effects of Exposure on Tumor Growth and Cell-mediated Tumor Immunity", J. Environmental, Vol. 4, pp. 65-79, 1980. | |
| | CI | ISHINISHI, et al., "Study on Chronic Toxicity of Arsenic Trioxide in Rats with Special Reference to the Liver Damages", Fukuoka Acta Medicine, 71:27, 1980 | |
| | CJ | Arsenic, Environmental Health Criteria, 18, Geneva: WHO, 1981 | |
| | CK | CUZICK et al., "Medicinal Arsenic and Internal Malignancies", Br. J. Cancer, 45:904-911, 1982 | |
| | CL | QI and BI, "Method for Removing As ₂ O ₃ from Realgar, Chung Yao Tung Pao, 8(5):21-22, 1983 | |
| | CM | KASPER et al., "Hepatic Angiosarcoma and Bronchioloalveolar Carcinoma Induced by Fowler's Solution", JAMA 252(24):3407-3408, 1984 | |
| | CN | ZHANG et al., "Clinical Study on the Treatment of Acute Promyelocytic Leukemia with Ai Ling #1", J. of Traditional Chinese and Western Medicine, Vol. 4, No. 1, p. 19, 1984. | |
| | CO | PERSHAGEN et al., "On the Pulmonary Tumorigenicity of Arsenic Trisulfide and Calcium Arsenate in Hamsters", Cancer Letters, 27:99-104, 1985 | |
| | CP | SHIMOTSUURA et al., "Studies on the Antineoplastic Actions of As ₂ O ₃ ", Shikwa Gakuho, 86:1237-1253, 1986 | |
| | CQ | YAMAMOTO et al., "Tumorigenicity of Inorganic Arsenic Compounds Following Intratracheal Installations to the Lungs of Hamsters", Int. J. Cancer 40:220-223, 1987 | |
| | CR | LEE et al., "Induction of Gene Amplification by Arsenic", Science, 241: 79-81, 1988 | |
| | CS | LI et al., "Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma", Chinese J. Oncology, 10:61-62, 1988 | |
| | CT | SUN, HONGDE et al., "32 Cases of Acute Early Granulocytic Leukemia Treated with Ai-Ling No. 1 in Combination with Chinese Medical Practice of Pattern Identification", Zhongguo Zhongxiyi Jiehe Zazhi, Vol. 12(3), 170-171, 1992 | |
| | CU | PENG, ZHANG et al., "Treatment of Acute Promyelocyte Leukemia with Intravenous Arsenic Trioxide", Chinese Journal of Hematology, Vol. 17, Translation, February 1996 | |
| | CV | Arsen (III)-Sulfid As ₂ S ₂ ", Gmelin's Arsenic, 8.sup.th Edition, 17:422-433, 1952 | |
| | CW | Diarsendisulfid As ₂ S ₂ ", Gmelin's Arsenic, 8.sup.th Edition, 17:417-422, 1952 | |
| | CX | Goodman & Gilman's "The Pharmacological Basis of Therapeutics", Ninth Edition, McGraw-Hill, Health Professions Division, pp. 1659-1662 | |
| | CY | "Inorganic Arsenic Compounds Other Than Arsenic Health and Safety Guide", Health and Safety Guide No. 70," WHO, Geneva 1992 | |
| | CZ | "Xionghuang, Realgar", Chinese Pharmacopoeia (I), Guangdong Science and Technology Publishing House, China, pp. 298-299, 1995 | |
| | CA1 | AKAO et al., "Arsenic Induces Apoptosis in B-cell Leukemic Cell Lines in Vitro: Activation of Caspases and Down-regulation of Bcl-2 Protein", British J of Hematology, 102, 1055-1060, 1998 ©Blackwell Science Ltd. | |
| | CB1 | ANDRE et al., "The PML and PML/RAR α Domains: From Autoimmunity to Molecular Oncology and From Retinoic Acid to Arsenic", Experimental Cell Research, 229:253-260, 1996 ©Academic Press, Inc. 1996 | |
| | CC1 | Chemical Abstract, 63-Pharmaceuticals 11:317, 111:219272j and 111:219276p, 1987-1991 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/759,290 |
| | | | | Filing Date | January 16, 2004 |
| | | | | First Named Inventor | Raymond P. Warrell, Jr. |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | A. N. Pryor |
| | | | | Attorney Docket Number | CELLTH 3.0-003 CONT CONT XVI |
| Sheet | 3 | of | 5 | | |

| | | |
|-----|---|--|
| CD1 | CHEN et al., "In Vitro Studies on Cellular and Molecular Mechanisms of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia: As ₂ O ₃ induces NB ₄ Cell Apoptosis with Down Regulation of Bcl-2 Expression and Modulation of PML-RAR α /PML proteins", Blood 88(3): 1052-1061, Aug. 1996. ©American Society of Hematology 1996 | |
| CE1 | CHEN et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL):I. As ₂ O ₃ Exerts Dose-Dependent Dual Effects on APL Cells", Blood 89(9):3345-3353, 1997 ©The American Society of Hematology 1997 | |
| CF1 | CHUNG et al., "Influence for Carcinoma Cell and Lymphatic Cell of Acetyl Arsonate", Yakhak Hoeji 40(5):599-607, 1996 (Abstract Only) | |
| CG1 | DE THE "L'oxyde d'arsenic: apres l'acide retinoique, un nouveau traitement cible dela leucemie aigue promyelocytaire" Medecine/Sciences, 13:867-71, 1997 | |
| CH1 | Dictionary of Inorganic Compounds, vol. 1, Ac-C ₁₀ , IC-0006667-IC-000671 (1992) | |
| CI1 | FLAMIGNI et al., "Effect of Sodium Arsenite on the Induction and Turnover of Ornithine Decarboxylase Activity in Erythroleukemia Cells", Cell Biochemistry and Function 7:213-217, 1989 | |
| CJ1 | Fluka, 1995/96 Catalog: 152-153 | |
| CK1 | GERMOLEC et al., "Arsenic Induces Overexpression of Growth Factors in Human Keratinocytes", Toxicology and Applied Pharmacology, 141:301-318, 1996 ©Academic Press, Inc., 1996 | |
| CL1 | HUANG et al., 1995, "The Clinical Study of QINGDAI Tablet for Treating Acute Promyelocytic Leukemia", China Magazine of Hematology, 16(1):26 | |
| CM1 | KONIG et al., "Comparative Activity of Melarsoprol and Arsenic Trioxide in Chronic B-Cell Leukemia Lines", Blood 90(2):562-570, 1997. ©The American Society of Hematology 1997 | |
| CN1 | KWONG et al., "Delicious Poison: Arsenic Trioxide for the Treatment of Leukemia", Blood 89:3487-8, 1997 | |
| CO1 | LU et al., "Effective treatment of AML-M3 (APL) and Their Remission Maintenance with Realgar: A Pilot Clinical and Laboratory Study on 38 Patients", Blood, 90 (10 Suppl. 1, part 1):416A, #1849, 1997 | |
| CP1 | LU et al., "Study of Reaglar in the Treatment of Acute Promyelocytic Leukemia (APL)-a pilot clinical and laboratory study on 32 Patients", China-Korea Medical Conference '97, 1997 | |
| CQ1 | MERVIS, "Ancient Remedy Performs New Tricks", Science 273:578, 1996 | |
| CR1 | NEUBAUER, "Arsenic Cancer: A Review", Arsenical Cancer, Arsenic Committee of the Medical Research Council, pp. 192-251, 1947 | |
| CS1 | REICHL et al., "Effect of Arsenic on Cellular Metabolism after Single or Repeated Injection in Guinea Pigs", Arch. Toxicol, Suppl. 13, p. 363-65, 1989 | |
| CT1 | Remington's Pharmaceutical Sciences, Mack Publishing Co., Easton, PA, pp. 1570-1580, 1990 | |
| CU1 | SCHENK, Handbook of Preparative Inorganic Chemistry, 1:603, G. Brauer, Ed., Academic Press, New York, 2.sup.nd Edition, 1963 | |
| CV1 | SHEN et al., "Use of Arsenic Trioxide (As ₂ O ₃) in the Treatment of Acute Promyelocytic Leukemia (APL):II Clinical Efficacy and Pharmacokinetics in Relapsed Patients", Blood 89(9):3354-3360, 1997 ©The American Society of Hematology 1997 | |
| CW1 | SOIGNET et al., "Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide", J of Medicine 339:19, 1998. ©Massachusetts Medical Society 1998 | |
| CX1 | TRELEAVEN et al., "Arsenic and Ayurveda", Leukemia and Lymphoma, 10:343-345, 1993 | |
| CY1 | USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD p. 59, Nov. 1994. | |
| CZ1 | WANG et al., "Studies on Chemically Preventing Leukemia", Ghung Hua Chung Liu Tsa Chih, 11(3):207-210, 1989 | |
| CA2 | XIANG et al., "60 Cases of Treating Acute Promyelocytic Leukemia by QINGDAI Tablet", Med. J. Chin. PLA 20(3):227-229, 1995 | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/759,290 |
| | | | | Filing Date | January 16, 2004 |
| | | | | First Named Inventor | Raymond P. Warrell, Jr. |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | A. N. Pryor |
| | | | | Attorney Docket Number | CELLTH 3.0-003 CONT CONT XVI |
| Sheet | 4 | of | 5 | | |

| | | | |
|--|-----|--|--|
| | CB2 | YUAN et al., "Research on Traditional Methods for Purifying Realgar", Chung Yao Tung Pao, 13(8):23-26, 1988 | |
| | CC2 | YUAN et al., "Exploring Methods for Purifying Realgar", Chung Yao Tung Pao, 13(8):17-21, 1988 | |
| | CD2 | ZHANG et al., "Traditional Chinese and Western Medicine in the Treatment of 27 Patients with Malignant Lymphoma," Chinese J. Oncology, 10:61-62, 1988 | |
| | CE2 | ZHANG et al., "Treatment of Acute Promyelocytic Leukemia with "713": Clinical Observations and Study of Action Mode on 117 patients", J. Harbin Medical Univ. 29(3):243, 1995 | |
| | CF2 | ZHANG et al., "Treatment of Acute Promyelocytic Leukemia with Intravenous Arsenic Trioxide", Chinese J. of Hematology 17(2) 1996 | |
| | CG2 | ZHU et al., "Arsenic-induced PML Targeting Onto Nuclear Bodies: implications for the treatment of acute promyelocytic leukemia", Proc. Natl. Acad. Sci. 94:3978-3983, 1997, ©The National Academy of Sciences of the USA 1997 | |
| | CH2 | "Letter on Historical Facts Regarding the Development of Ai Ling No. 1 and the Clinical Use of Arsenic Trioxide in the Treatment of Acute Promyelocytic Leukemia and a Study of Its Mechanism", Heilongjiang Branch of the Chinese Medical Association, Mar. 27, 1998. | |
| | CI2 | WANG et al., "Arsenic Trioxide and Melarsprol Induced Programmed Cell Death in Myeloid Leukemia Cell Lines and Function in PML and PNL-RAR α Independent Manner", Blood, 92(5):1497-1504, 1998 | |
| | CJ2 | USP Dictionary of USAN and International Drug Names, United States Pharmacopeial Conventions, Inc., Rockville, MD, p. 59, Nov. 1995. | |
| | CK2 | WANG et al., "Arsenic and the Treatment of Leukemia", J Harbin Medical Univ., vol. 31, No. 5, Oct. 1997 | |
| | CL2 | SMORENBURG et al., "Randomized Cross-Over Evaluation of Body-Surface Area-Based Dosing Versus Flat-Fixed Dosing of Paclitaxel", J. Clin. Oncology, 21:197-202 (2003) | |
| | CM2 | VOISEN et al., "Extrapolation of Animal Toxicity to Humans: Interspecies Comparisons in Drug Development", Regulatory Toxicology and Pharmacology, 12:107-116 (1990) | |
| | CN2 | FREIRICH et al., "Quantitative Comparison of Toxicity of Anticancer Agents in Mouse, Rat, Hamster, Dog, Monkey and Man", Cancer Chemotherapy Reports, 50:219-244 (1966) | |
| | CO2 | GURNEY, "How to Calculate the Dose of Chemotherapy", Brit. J. Cancer, 86:1297-1302 (2001) | |
| | CP2 | SHARKEY et al., "Body Surface Area Estimation in Children Using Weight Alone: Application in Paediatric Oncology", Brit. J. Cancer, 85(1):23-8 (2001) | |
| | CQ2 | AU et al., "Arsenic Trioxide in Comparison with Chemotherapy and Bone Marrow Transplantation for the Treatment of Relapsed Acute Promyelocytic Leukaemia", Annals of Oncology, 14:752-757 (2003) | |
| | CR2 | ZHANG et al., "Pathologic, Cytogenetic and Molecular Assessment of Acute Promyelocytic Leukemia Patients Treated with Arsenic Trioxide (As ₂ O ₃)", Modern Pathology; (2000); pp. 954-961 | |
| | CS2 | WESTERVELT et al.; "Sudden Death Among Patients with Acute Promyelocytic Leukemia Treated with Arsenic Trioxide"; Blood (2001); vol. 98, No. 2, pp. 266-271. | |
| | CT2 | SOIGNET et al.; "United States Multicenter Study of Arsenic Trioxide in Relapsed Acute Promyelocytic Leukemia", Journal of Clinical Oncology, (2001), vol. 19, No. 18, pp. 3852-3880 | |
| | CU2 | WESERVELT et al., "Response and Toxicity Associated with Dose Escalation of Arsenic Trioxide in the Treatment of Resistant Acute Promyelocytic Leukemia", Blood 90 (10) (1997), p. 2496 | |
| | CV2 | SOIGNET et al., "Initial Clinical Study of a Novel Organic Arsenical, Melarsoprol, in Patients with Advanced Leukemia", Blood (W.B., Saunders, Philadelphia, PA), vol. 88, No. 10, p. 219A (ISSN: 0006-4971) (1996) | |

| | | | |
|--------------------|--|-----------------|--|
| Examiner Signature | | Date Considered | |
|--------------------|--|-----------------|--|

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

| | | | | | |
|---|---|----|---|--------------------------|------------------------------|
| Substitute for form 1449A/B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i> | | | | Complete if Known | |
| | | | | Application Number | 10/759,290 |
| | | | | Filing Date | January 16, 2004 |
| | | | | First Named Inventor | Raymond P. Warrell, Jr. |
| | | | | Art Unit | 1616 |
| | | | | Examiner Name | A. N. Pryor |
| Sheet | 5 | of | 5 | Attorney Docket Number | CELLTH 3.0-003 CONT CONT XVI |

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

| | | | |
|-----------------------|--|--------------------|--|
| Examiner Signature | | Date Considered | |
|-----------------------|--|--------------------|--|